Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jun 15, 2023 8:54pm
177 Views
Post# 35499293

RE:RE:ONCY's pelareorep activates interferon (IFN) signalling

RE:RE:ONCY's pelareorep activates interferon (IFN) signallingRepost :

Hypoxia-inducible factor-1α (HIF-1a) is a direct transcriptional suppressor of interferon regulatory factors, the transcriptional activators of type I IFN.

These findings may aid in understanding and control of impaired IFN production by severe acute respiratory syndrome coronavirus 2 infection .... and why Big Pharma companies like Pfizer, Moderna, BMS, Roche, MerckKGaA and others are be interested in ONCY as an acquisition targert - since these Big Pharma coompanies and others, have all been involved in the development of various Covid-19 vaccine therapies and now want to pursue vaccines (oncolytic virus) in the treatment of cancer.

These Big Pharma companies have developed their own "proof-of-concept" studies around vaccines and have become more knowledgeable in the concept of using an oncolytic virus like ONCY's pelareorep, in the treatment of cancer since 
ONCY's oncolytic virus pelareorep down-regulates HIF-1a which inturn down-regulates adenosine, a downstream chemokine-like catalyst in the TME hypoxia pathway, that acts as a potent TME immunosuppressive agent.

https://www.pnas.org/doi/10.1073/pnas.2106017118
<< Previous
Bullboard Posts
Next >>